Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Leonardo Mirandola, Diane D. Nguyen, Rakhshanda L. Rahman, Fabio Grizzi, Yu Yuefei, José A. Figueroa, Marjorie R. Jenkins, Everardo Cobos & Maurizio Chiriva-Internati. (2014) Anti-Galectin-3 Therapy: A New Chance for Multiple Myeloma and Ovarian Cancer?. International Reviews of Immunology 33:5, pages 417-427.
Read now
Read now
Sevtap Savas. (2012) A curated database of genetic markers from the angiogenesis/VEGF pathway and their relation to clinical outcome in human cancers. Acta Oncologica 51:2, pages 243-246.
Read now
Read now
Kenneth S. Cohen. (2011) Angiogenesis and multiple myeloma: is there a role for angiogenic biomarkers in the context of autologous stem cell transplant?. Leukemia & Lymphoma 52:7, pages 1173-1175.
Read now
Read now
Christopher R. Friese, Gregory A. Abel, Lysa S. Magazu, Bridget A. Neville, Lisa C. Richardson & Craig C. Earle. (2009) Diagnostic delay and complications for older adults with multiple myeloma. Leukemia & Lymphoma 50:3, pages 392-400.
Read now
Read now
Articles from other publishers (31)
Masahiro Hiasa, Takeshi Harada, Eiji Tanaka & Masahiro Abe. (2021) Pathogenesis and treatment of multiple myeloma bone disease. Japanese Dental Science Review 57, pages 164-173.
Crossref
Crossref
Gabriela Rozic, Lena Paukov, Ziv Cohen, Irit Shapira, Adrian Duek, Ohad Bejamini, Abraham Avigdor, Arnon Nagler, Igor Koman & Merav Leiba. (2018)
STK405759 as a combination therapy with bortezomib or dexamethasone, in
in vitro
and
in vivo
multiple myeloma models
. Oncotarget 9:59, pages 31367-31379.
Crossref
Crossref
Xin Zhang & Hesheng Luo. (2017) Effects of thalidomide on growth and VEGF-A expression in SW480 colon cancer cells. Oncology Letters.
Crossref
Crossref
Evangelos Terpos, Dimitris Matsaridis, Vassilis Koutoulidis, Flora Zagouri, Dimitrios Christoulas, Sophia Fontara, Evangelia Panourgias, Maria Gavriatopoulou, Efstathios Kastritis, Meletios A. Dimopoulos & Lia A. Moulopoulos. (2017) Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma. Annals of Hematology 96:10, pages 1707-1714.
Crossref
Crossref
Rimma Berenstein, Axel Nogai, Marlies Waechter, Olga Blau, Aline Kuehnel, Martin Schmidt-Hieber, Annegret Kunitz, Antonio Pezzutto, Bernd Dörken & Igor Wolfgang Blau. (2016) Multiple myeloma cells modify VEGF/IL-6 levels and osteogenic potential of bone marrow stromal cells via Notch/miR-223. Molecular Carcinogenesis 55:12, pages 1927-1939.
Crossref
Crossref
K K Starheim, T Holien, K Misund, I Johansson, K A Baranowska, A-M Sponaas, H Hella, G Buene, A Waage, A Sundan & G Bjørkøy. (2016) Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells. Blood Cancer Journal 6:7, pages e446-e446.
Crossref
Crossref
Pilar de la Puente, Barbara Muz, Rebecca C. Gilson, Feda Azab, Micah Luderer, Justin King, Samuel Achilefu, Ravi Vij & Abdel Kareem Azab. (2015) 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma. Biomaterials 73, pages 70-84.
Crossref
Crossref
Maximilian Merz, Judith Ritsch, Christina Kunz, Barbara Wagner, Sandra Sauer, Dirk Hose, Thomas Moehler, Stefan Delorme, Hartmut Goldschmidt, Christian Zechmann & Jens Hillengass. (2015) Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessment of Antiangiogenic Treatment Effects in Multiple Myeloma. Clinical Cancer Research 21:1, pages 106-112.
Crossref
Crossref
Sudipa S. Roy, Nameer B. Kirma, Bindu Santhamma, Rajeshwar R. Tekmal & Joseph K. Agyin. (2014) Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells. Cancer Chemotherapy and Pharmacology 73:6, pages 1263-1271.
Crossref
Crossref
Marina Ferrarini, Nathalie Steimberg, Maurilio Ponzoni, Daniela Belloni, Angiola Berenzi, Stefania Girlanda, Federico Caligaris-Cappio, Giovanna Mazzoleni & Elisabetta Ferrero. (2013) Ex-Vivo Dynamic 3-D Culture of Human Tissues in the RCCS™ Bioreactor Allows the Study of Multiple Myeloma Biology and Response to Therapy. PLoS ONE 8:8, pages e71613.
Crossref
Crossref
L Bolkun, D Lemancewicz, K Sobolewski, M Mantur, J Semeniuk, A Kulczynska, J Kloczko & J Dzieciol. (2013) The evaluation of angiogenesis and matrix metalloproteinase-2 secretion in bone marrow of multiple myeloma patients before and after the treatment. Advances in Medical Sciences 58:1, pages 118-125.
Crossref
Crossref
Evangelos Terpos. (2013) Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma. Medical Science Monitor 19, pages 1188-1194.
Crossref
Crossref
G. David Roodman. 2013. Genetic and Molecular Epidemiology of Multiple Myeloma. Genetic and Molecular Epidemiology of Multiple Myeloma
97
120
.
S. Watson & T. de La Motte Rouge. (2012) Antiangiogéniques: les anciens et les nouveauxAngiogenesis: old and new agents. Oncologie 14:4, pages 216-225.
Crossref
Crossref
Evangelos Terpos, Konstantinos Anargyrou, Eirini Katodritou, Efstathios Kastritis, Athanasios Papatheodorou, Dimitrios Christoulas, Anastasia Pouli, Eurydiki Michalis, Sosana Delimpasi, Maria Gkotzamanidou, Nikitas Nikitas, Vasilios Koumoustiotis, Dimitrios Margaritis, Konstantinos Tsionos, Ekaterini Stefanoudaki, John Meletis, Konstantinos Zervas & Meletios A. Dimopoulos. (2012) Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. International Journal of Cancer 130:3, pages 735-742.
Crossref
Crossref
Leonardo Mirandola, Yuefei Yu, Constance M. John, Marjorie Jenkins, Everardo Cobos & Maurizio Chiriva-Internati. 2012. Galectins and Disease Implications for Targeted Therapeutics. Galectins and Disease Implications for Targeted Therapeutics
289
307
.
Nicola Giuliani, Paola Storti, Marina Bolzoni, Benedetta Dalla Palma & Sabrina Bonomini. (2011) Angiogenesis and Multiple Myeloma. Cancer Microenvironment 4:3, pages 325-337.
Crossref
Crossref
Jiangqin Sun, Dingguo Liu & Zhimin Wang. 2011. Chiral Drugs. Chiral Drugs
401
448
.
Leonardo Mirandola, Yuefei Yu, Kitty Chui, Marjorie R. Jenkins, Everardo Cobos, Constance M. John & Maurizio Chiriva-Internati. (2011) Galectin-3C Inhibits Tumor Growth and Increases the Anticancer Activity of Bortezomib in a Murine Model of Human Multiple Myeloma. PLoS ONE 6:7, pages e21811.
Crossref
Crossref
Rajeev S. Samant & Lalita A. Shevde. (2011) Recent Advances in Anti-Angiogenic Therapy of Cancer. Oncotarget 2:3, pages 122-134.
Crossref
Crossref
Kenneth C. AndersonRuben D. Carrasco. (2011) Pathogenesis of Myeloma. Annual Review of Pathology: Mechanisms of Disease 6:1, pages 249-274.
Crossref
Crossref
Hyun Jung Kim, Sung-Moo Kim, Kyung-Ran Park, Hyeung-Jin Jang, Young-Soon Na, Kyoo Seok Ahn, Sung-Hoon Kim & Kwang Seok Ahn. (2011) Decursin chemosensitizes human multiple myeloma cells through inhibition of STAT3 signaling pathway. Cancer Letters 301:1, pages 29-37.
Crossref
Crossref
P. J. Simpson-Haidaris, S. J. Pollock, S. Ramon, N. Guo, C. F. Woeller, S. E. Feldon & R. P. Phipps. (2010)
Anticancer Role of PPAR
Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes
. PPAR Research 2010, pages 1-36.
Crossref
Crossref
Pei Lin. (2009) Plasma Cell Myeloma. Hematology/Oncology Clinics of North America 23:4, pages 709-727.
Crossref
Crossref
Peter H. Wiernik. (2008) Treatment of Hematologic Neoplasms with New Immunomodulatory Drugs (IMiDs). Current Treatment Options in Oncology 10:1-2, pages 1-15.
Crossref
Crossref
Evangelos Terpos, Anna Tasidou, Efstathios Kastritis, Evangelos Eleftherakis-Papaiakovou, Maria Gavriatopoulou, Magdalini Migkou & Meletios-Athanassios Dimopoulos. (2009) Angiogenesis in Waldenström's Macroglobulinemia. Clinical Lymphoma and Myeloma 9:1, pages 46-49.
Crossref
Crossref
Pei Lin. (2009) Plasma cell neoplasms. Diagnostic Histopathology 15:3, pages 134-141.
Crossref
Crossref
Efstathios Kastritis, Andreas Charidimou, Andreas Varkaris & Meletios A. Dimopoulos. (2009) Targeted therapies in multiple myeloma. Targeted Oncology 4:1, pages 23-36.
Crossref
Crossref
Agata Rydzewska, Katarzyna Ślepokura, Tadeusz Lis, Paweł Kafarski & Piotr Młynarz. (2009) Unexpected formation of hydroxyborazaphosphonic acid in the reaction of (N-benzyl)benzylideneimine-2-boronic acid with diethyl phosphite. Tetrahedron Letters 50:1, pages 132-134.
Crossref
Crossref
William W. Li, Michelle Hutnik & Gerald Gehr. (2008) Antiangiogenesis in haematological malignancies. British Journal of Haematology 143:5, pages 622-631.
Crossref
Crossref
Béla Telek, Leonóra Méhes, Péter Batár, Attila Kiss & Miklós Udvardy. (2008) Effective PAD (bortezomib, doxorubicine, dexamethasone) treatment of a patient with plasma cell leukaemia developed after autologous stem cell transplantation. Orvosi Hetilap 149:41, pages 1957-1959.
Crossref
Crossref